SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
January 28, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
January 27, 2025 06:00 ET
|
Alvotech
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
January 23, 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo® in Central & Eastern Europe
January 14, 2025 08:00 ET
|
Er-Kim
Er-Kim's partnership will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease
USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
January 14, 2025 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Groupe PAT : La SFHBB franchit le seul des 5% du capital de Plant Advanced Technologies PAT
January 13, 2025 02:00 ET
|
Plant Advanced Technologies
Paris et Vandœuvre-lès-Nancy, le 13 janvier 2025 – 08 : 00 (CET)Communiqué de pressePour diffusion immédiate Franchissement du seuil de 5% Plant Advanced Technologies PAT (Euronext Growth™- Paris -...
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
December 23, 2024 04:00 ET
|
Alvotech
Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes REYKJAVIK, Iceland, Dec. 23, 2024 ...
Groupe PAT : PAT participe au projet européen de recherche « Bryomolécules »
December 16, 2024 02:00 ET
|
Plant Advanced Technologies
Vandœuvre-lès-Nancy, le 16 décembre 2024 - 08 : 00 (CET) Communiqué de pressePour diffusion immédiate PAT participe au projet européen de recherche « Bryomolécules » Plant Advanced Technologies PAT...
BetterLife Announces Favorable Outcome in New York Legal Claims
December 09, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of...
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
November 25, 2024 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...